Clinical trial
Women's Triple-Negative First-Line Study: A Phase II Trial of Mirvetuximab Soravtansine in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy (NACT), Including a Lead-In Cohort to Establish Activity in Patients With Metastatic TNBC
NCT03106077 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Women's Triple-Negative First-Line Study: A Phase II Trial of Mirvetuximab Soravtansine in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy (NACT), Including a Lead-In Cohort to Establish Activity in Patients With Metastatic TNBC
- Lead sponsor
- M.D. Anderson Cancer Center
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 5, 2017
- Completion date
- October 1, 2019
- Enrollment
- 96 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
anatomic stage ii breast cancer ajcc v8, anatomic stage iia breast cancer ajcc v8, anatomic stage iib breast cancer ajcc v8, anatomic stage iii breast cancer ajcc v8, anatomic stage iiia breast cancer ajcc v8, anatomic stage iiib breast cancer ajcc v8, anatomic stage iiic breast cancer ajcc v8, anatomic stage iv breast cancer ajcc v8, estrogen receptor negative, folate receptor alpha positive, her2/neu negative, progesterone receptor negative, prognostic stage ii breast cancer ajcc v8, prognostic stage iia breast cancer ajcc v8, prognostic stage iib breast cancer ajcc v8, prognostic stage iii breast cancer ajcc v8, prognostic stage iiia breast cancer ajcc v8, prognostic stage iiib breast cancer ajcc v8, prognostic stage iiic breast cancer ajcc v8, prognostic stage iv breast cancer ajcc v8, triple-negative breast carcinoma